Search

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

肾脏是体内具有高代谢率的器官之一，能量代谢是维持肾单位不同细胞结构和功能的基础。应激环境中 近端小管上皮细胞更容易发生代谢重编程，由于缺氧、线粒体功能障碍和营养感知通路紊乱，肾小管上皮细胞的代 谢过程从脂肪酸β氧化（FAO）转变为糖酵解。尽管糖酵解增强可弥补能量消耗，但持续的FAO受抑和糖酵解增强 可引起炎症、脂质堆积和纤维化。早期改善线粒体功能和恢复FAO对于延缓慢性肾脏病进展有重要价值。 [ABSTRACT FROM AUTHOR]

Objective To prepare the paclitaxel-loaded polylactic acid microspheres (PTX-PLLA-MPS), to establish the content determination method, to optimize the preparation process, and to preliminarily evaluate its in vitro release behavior and anti-gastric cancer activity. Methods PTX-PLLA-MPS was prepared by solvent evaporation method. The content of paclitaxel in PTX-PLLA-MPS was determined by high-performance liquid chromatography and the drug loading and encapsulation efficiency were calculated. The preparation process was optimized through orthogonal experiments based on the evaluation indicators of drug loading and encapsulation efficiency. The morphology was observed with an optical microscope, the particle size and Zeta potential were measured by a particle size analyzer, and the release behavior in vitro was investigated by high performance liquid chromatography. We adjusted the cell concentration of gastric cancer SGC7901 cells to 4×106 /mL, and inoculated the cells in 96-well plates. After overnight culture, the blank microsphere group, PTX group, and PTX-PLLA-MPS group were randomly set up, and 30 µg/mL blank microspheres，30 µg/mL PTX, and 30 µg/mL PTX-PLLA-MPS were added for treatment of 24，48 ，72 h. We added CCK-8 solution to calculate cell viability in each group, used trypsin to digest human gastric cancer cells SGC7901, adjusted the cell concentration, and injected subcutaneously into the axilla of the forelimb of nude mice with an injection volume of 0. 2 mL/mouse to establish the nude mouse tumor-bearing models. Fifteen nude mice with tumors were selected and randomly divided into three groups according to their body weight： model group, PTX group, and PTX-PLLA-MPS group. They were injected through the tail vein, once every 2 days, at a dose of 15 mg/kg, and the tumor growth curve was plotted. Results It was showed that PTX-PLLA-MPS was optimally prepared with an aqueous PVA solution of 1. 0%, an oil/water volume ratio of 1：10, a PLLA concentration of 6%, and a PLLA/PTX ratio of 6：1, and the resulting microspheres were round with a mean particle size of (1. 23 ± 0. 21) µm, a zeta potential of (3. 67 ± 1. 42) mV, and a mean drug loading capacity of 18. 23% ± 1. 40%, encapsulation rate of 74. 00% ± 1. 49%, cumulative in vitro release rate of 76. 20% ± 3. 46% in 21 days. The cell viability of the blank microsphere group, PTX group, and PTX-PLLA-MPS group decreased sequentially over the time. The tumor volume of the model group, PTX group and PTX-PLLA-MPS group showed an increasing trend with time. After 28 d, the tumor volume of the PTX-PLLA-MPS group was larger than that of the PTX group (P<0. 05), and the tumor volume of the PTX group was smaller than that of the model group (P<0. 05) . Conclusion PTX-PLLA-MPS were successful prepared with good morphology, high encapsulation rate loading, slow release properties, and significant anti-gastric cancer activity . [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To explore the association between adverse drug reactions (ADRs) and methylenetetrahydrofolate reductase (MTI:IFR) C677T gene polymorphism in patients with rheumatoid arthritis ( RA) treated with methotrexate (MTX). Methods Totally 178 RA patients were selected. Single nucleotide polymorphism (SNP) of MTHFR [677C > T ( rs1801133) J was detected by TaqMan fluorescence PCR. The ADRs that occurred in 178 patients during treatment with MTX were reviewed, and the association between gene polymorphism and ADRs was analyzed. Results Among 178 RA patients, 71 cases had adverse reactions, including 35 cases of hematological toxicity, 31 cases of gastrointestinal reactions, 7 cases of liver toxicity, 6 cases of reproductive system toxicity, 4 cases of renal toxicity, and 7 cases of others diseases. Of the 178 subjects, CC genotypes were found in 71 cases, CT genotypes in 76 cases, and TT genotypes in 31 cases. Of the 71 patients with adverse reactions, CC genotypes were found in 31 cases, CT genotypes in 23 cases, and TT genotypes in 17 cases. Among all genotypes of MTI:IFR C677T in RA patients, the incidence of MTX-related ADRs in TT genotype was the highest (about 54. 8%), CC genotype was the second (43. 7%), and CT genotype was the lowest (30. 3 %), with statistically significant differences (all P < 0. 05). However, there was no statistically significant difference in the incidence of different types of ADRs in RA patients with different genotypes when using MTX (P > 0. 05). When we analyzed the patients' blood routine, we found that the red blood cell volume (MCV) in the later period was higher than that in the initial period, but this change was not statistically different among all genotypes (P >0. 05). Conclusion The occurrence of MTX-related ADRs is related to MTHFR C677T gene polymorphism in RA patients, and individuals with TI genotype are more likely to suffer from MTX-related ADRs. [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的探讨2型糖尿病合并冠心病患者血清炎性标志物降钙素原(PCT)、同型半胱氨酸（Hey)和超敏C 反应蛋白（hs-CRP)水平变化对冠状动脉病变的影响。方法将人选的154例患者分为单纯糖尿病组40例与糖尿 病合并冠心病组114例（其中急性心肌梗死21例、陈旧性心肌梗死33例、不稳定型心绞痛29例及稳定型心绞痛 31例）。比较单纯糖尿病组与糖尿病合并冠心病组以及糖尿病合并不同类型冠心病、不同冠脉病变支数、不同 Gensini积分患者血清PCT、Hcy和hs-CRP水平，采用Logistic回归分析PCT、Hcy和hs-CRP水平与冠脉病变的关 系结果糖尿病合并冠心病患者组PCT、Hcy和hs-CRP水平均高于单纯糖尿病组;糖尿病合并急性心梗PCT、 Hey和hs-CRP水平高于陈旧性心梗、不稳定定型心绞痛和稳定型心绞痛;合并不稳定型心绞痛PCT水平高于合并 陈旧性心梗和稳定性心绞痛(P均<0.05);三支冠脉病变PCT、Hcy和hs-CRP水平高于单支或双支冠脉病变(P均 <0.05) ;T2DM合并CHD组Gensini积分越髙，Hey、PCT及hs-CRP水平越高（P均<0.05) ;Logistic 回归分析示 Hey、PCT、hs-CRP水平与冠脉病变支数均存在相关性(P均<0.05) e结论 2型糖尿病合并冠心病患者冠状动脉 病变程度随血清炎症标志物PCT、Hcy和hs-CRP水平升高而加重。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的：探讨趋化因子CXCL12、基质金属蛋白酶9(MMP-9)及整合素β1(integrinβ1)在卵巢癌发生、发展中的作用。方法选取60例份卵巢癌组织、20例份卵巢交界性肿瘤组织及10例份卵巢良性肿瘤组织，采用免疫组化Envision法检测CXCL12、MMP-9及integrin β1阳性表达率，分析CXCL12、MMP-9及integrin β1阳性表达与卵巢癌患者临床病理参数的关系及卵巢癌组织中CXCL12、MMP-9、integrinβ1表达的关系。结果卵巢癌组织中CX-CL12、MMP-9及integrinβ1阳性表达率均高于卵巢交界性肿瘤组织及卵巢良性肿瘤组织(P均<0．01)。 CXCL12阳性表达与卵巢癌临床分期、淋巴结转移及腹水有关(P<0．05或<0．01)，MMP-9及integrin β1表达均与卵巢癌组织学分级、TNM分期、淋巴结转移及腹水有关( P<0．05或<0．01)。卵巢癌组织中CXCL12表达与MMP-9及in-tegrinβ1表达均呈正相关(r分别为0．328、0．332，P均为0．001)，MMP-9表达与integrin β1表达呈正相关(r＝0．447，P＝0．000)。结论卵巢癌组织CXCL12、MMP-9及integeinβ1均高表达，三者协同作用，共同促进卵巢癌的发生、发展。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的：分析先天性肾性尿崩症（CNDI）伴低促性腺激素性性腺功能减退症（HH）的临床诊治特点。方法回顾性分析1例CNDI伴HH患儿的临床诊治资料，并复习相关文献。结果患者男，10岁，以多饮、多尿和性腺发育延迟为主要表现；禁水试验阳性；试验性醋酸去氨加压素治疗3天，多饮、多尿症状无明显改善；卵泡刺激素和黄体生成素减低，睾酮增加幅度稍低；基因检测提示精氨酸加压素受体2（AVPR2）基因纯合突变。 AVPR2基因突变所致CNDI诊断明确，同时考虑伴有HH。给予调整饮食结构，低钠饮食；口服氢氯噻嗪50 mg／次、2次／天，肌肉注射绒毛膜促性腺激素2000 IU／次、2次／周，治疗1个月后复诊，多饮、多尿症状明显改善。继续用上述药物治疗3个月后复诊，睾丸体积无明显改善，睾酮0．38 ng／mL，临床效果欠佳。给予人绒毛膜促性腺激素（2000 IU／次、2次／周）联合人绝经期促性腺激素（75 IU／次、2次／周），治疗6个月复查睾丸体积较前增大（2 mL），睾酮水平较前升高（0．6 ng／mL），效果较好。结论 CNDI合并HH患儿临床少见，根据临床症状体征及基因筛查可明确诊断，给予调整饮食、氢氯噻嗪及促性腺激素治疗效果较好。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To observe the expression changes of CXC chemokine receptor 4 (CXCR4) and matrix metalloproteinase 9 (MMP-9) in ovarian carcinoma tissues, and to investigate their clinical significance. Methods The expression of CXCR4 and MMP-9 in 60 cases of ovarian carcinoma (group A) , 20 cases of borderline tumor (group B) and 10 cases of benign tumor (group C) was examined by immunohistochemical method. The correlation between them and their correlations with the clinicopathological parameters were analyzed. Results The positive expression rates of CXCR4 in the group A, group B and group C were 58.33% (35/60), 20.00% (4/20) and 10.00% (1/10), respectively. There was a statistically significant difference between group A and groups B and C (all P<0.05). The positive expression rates of MMP-9 in the group A, group B and group C were 83.33% (50/60), 35.00% (7/20) and 20.00% (2/10), respectively. Significant difference was found when we compared group A with groups B and C (all P<0.05). In ovarian carcinoma, the expression of CXCR4 protein was related with TNM stage and lymph-node metastasis; the expression of MMP-9 protein was related with tumor histological grade, TNM stage and lymph-node metastasis ( all P<0.05) . The CXCR4 expression was positively correlated with the expression of MMP-9 in the ovarian carcinoma tissues (r=0.257, P<0.05). Conclusions The expression of CXCR4 and MMP-9 is increased in the ovarian carcinoma tissues, which may play an im-portant role in the carcinogenesis and development of ovarian carcinoma.The combined detection of CXCR4 and MMP-9 may provide scientific experimental evidence for targeted therapy. [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)